港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

科倫博泰生物-B

285.400

-3.600-1.25%

成交量：81.19萬

成交額：2.33億

市值：647.86億

市盈率：-223.07

高：294.000

開：285.000

低：275.000

收：289.000

資料載入中...

總覽公司新聞公告

科倫博泰生物(06990.HK)將於美國披露蘆康沙妥珠單抗治療癌症研究成果

阿斯达克财经

科倫博泰生物-B(06990.HK)：核心產品蘆康沙妥珠單抗(SAC-TMT)於2025年ASCO GU癌症研討會上公佈的研究成果

【券商聚焦】海通國際：創新藥發展需要有活力的土壤

國金證券：醫藥AI應用熱度高漲值得佈局傳統主線季報或迎反轉

【券商聚焦】招銀國際指中國醫藥開啓估值修復

招銀國際：看好中國醫藥行業估值修復推薦“買入”藥明康德(02359)等

科倫博泰生物與控股股東科倫藥業續簽物業及設備租賃協議

科倫博泰生物-B(06990)：西妥昔單抗N01注射液獲國家藥品監督管理局批准上市

科倫博泰生物－Ｂ(06990.HK)治療直腸癌注射液獲批上市

阿斯达克财经

科倫博泰生物-B現漲近6% 和鉑醫藥宣佈HBM9378/SKB378獲批臨牀試驗

科倫博泰生物-B(06990)上漲5.12%，報170.5元/股

科倫博泰生物-B盤中異動臨近午盤股價大漲5.12%報170.500港元

港股異動 | 科倫博泰生物-B(06990)再漲近5% 和鉑醫藥宣佈HBM9378/SKB378獲批臨牀試驗

科倫博泰生物-B擬實施H股全流通

【科倫博泰生物-B(06990.HK)擬實施H股全流通】科倫博泰生物-B(06990.HK)發佈公告，公司董事會已審議及批准公司若干股東所持不超過約2542.12萬股公司內資股擬實施全流通(“H股全流通”)。同日，公司已向中國證監會提交關於H股全流通的備案申請。

科倫博泰生物-B(06990)擬實施H股全流通

科倫博泰生物-B盤中異動股價大跌5.04%報160.200港元

科倫博泰生物－Ｂ(06990)股價下跌5.039%，現價港幣$160.2

阿斯达克财经

格隆匯個股放量排行榜 | 1月26日

科倫博泰生物-B盤中異動早盤股價大漲5.09%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/06990/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科倫博泰生物-B","latestPrice":285.4,"timestamp":1744877289037,"preClose":289,"halted":0,"volume":811904,"delay":0,"floatShares":131000000,"shares":227000000,"eps":-1.2794172878344496,"marketStatus":"復活節星期一休市","change":-3.6,"latestTime":"04-17 16:08:09","open":285,"high":294,"low":275,"amount":232778521,"amplitude":0.065744,"askPrice":286.4,"askSize":300,"bidPrice":285.4,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.2794172878344496,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":289,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"volumeRatio":1.0355934219983844,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":131000000,"roa":"-3.41%","roe":"-9.46%","lyrEps":-1.279417,"volumeRatio":1.0355934219983844,"shares":227000000,"dividePrice":0,"high":294,"amplitude":0.065744,"preClose":289,"low":275,"week52Low":120.2,"pbRate":"18.42","psRate":"31.53","week52High":346,"institutionHeld":0,"latestPrice":285.4,"eps":-1.2794172878344496,"divideRate":0,"volume":811904,"delay":0,"ttmEps":-1.2794172878344496,"open":285,"prevYearClose":163.3,"prevWeekClose":285.4,"prevMonthClose":290.8,"prevQuarterClose":290.8,"fiveDayClose":280.8,"twentyDayClose":259.4,"sixtyDayClose":162.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510102878","title":"科倫博泰生物(06990.HK)將於美國披露蘆康沙妥珠單抗治療癌症研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2510102878","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510102878?lang=zh_tw&edition=fundamental","pubTime":"2025-02-11 08:19","pubTimestamp":1739233140,"startTime":"0","endTime":"0","summary":"科伦博泰生物公布，将在于2月13日至2月15日于美国圣弗朗西斯科举行的2025年美国临床肿瘤学会泌尿生殖系统癌症研讨会上，公布其抗人滋养细胞表面抗原2的抗体药物偶联物芦康沙妥珠单抗(佳泰莱)单药治疗既往接受过抗癌疗法时或治疗后病情进展的不可切除、局部晚期或转移性尿路上皮癌患者的1/2期KL264-01/MK-2870-001研究的疗效及安全性结果。上述研究的摘要亦将于当地时间2月10日发布在2025年ASCO GU癌症研讨会的官方网站上。沽空资料截至 2025-02-10 16:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1416187/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2510121888","title":"科倫博泰生物-B(06990.HK)：核心產品蘆康沙妥珠單抗(SAC-TMT)於2025年ASCO GU癌症研討會上公佈的研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2510121888","media":"格隆汇","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510121888?lang=zh_tw&edition=fundamental","pubTime":"2025-02-11 07:42","pubTimestamp":1739230934,"startTime":"0","endTime":"0","summary":"上述研究的摘要亦将于当地时间2025年2月10日发布在2025年ASCO GU癌症研讨会的官方网站上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/11074248065082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2510835332","title":"【券商聚焦】海通國際：創新藥發展需要有活力的土壤","url":"https://stock-news.laohu8.com/highlight/detail?id=2510835332","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510835332?lang=zh_tw&edition=fundamental","pubTime":"2025-02-10 16:32","pubTimestamp":1739176331,"startTime":"0","endTime":"0","summary":"创新药是劳动和研发密集型产业，其生态如此重要，在于Biopharma和MNC的诞生需要各企业在不同风险领域推动研发，拥有世界级销售能力的企业推动商业化。因此，创新药领域最为耀眼的投资策略，就是挖掘有成长潜质的Biotech和Biopharma，以及不断自我迭代和外延的MNC，其内核是投资符合疾病谱趋势的领域，以及有潜力的技术赛道。该行认为，中国的创新药投资机遇也基于两条主线。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1952832","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348784397.USD","LU0196878994.USD","159992","06978","BK1583","LU1969619763.USD","LU0307460666.USD","IE00B5MMRT66.SGD","BK1574","IE00B543WZ88.USD","LU0588546209.SGD","LU2328871848.SGD","LU0417516571.SGD","BK1500","BK1588","06160","09926","LU0348783233.USD","06990","LU2488822045.USD","BK1161","IE00BPRC5H50.USD","LU1794554557.SGD","LU1720050803.USD"],"gpt_icon":0},{"id":"2510488067","title":"國金證券：醫藥AI應用熱度高漲值得佈局 傳統主線季報或迎反轉","url":"https://stock-news.laohu8.com/highlight/detail?id=2510488067","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510488067?lang=zh_tw&edition=fundamental","pubTime":"2025-02-10 15:55","pubTimestamp":1739174146,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，随着人工智能技术的发展与进步，AI在赋能医药医疗、推动行业升级方面不断取得新进展，人工智能在医药健康领域的应用有望进入加速发展阶段。投资建议在布局医药AI投资方面，建议围绕三大领域：1)医疗设备与诊断影像；2)药物设计和研发；3)互联网医疗与大健康展开医疗人工智能投资布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1247726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0201","BK0183","BK0012","600109","BK0188","LU0196878994.USD","BK0276","BK1161","150130","06990","BK0028"],"gpt_icon":0},{"id":"2510889645","title":"【券商聚焦】招銀國際指中國醫藥開啓估值修復","url":"https://stock-news.laohu8.com/highlight/detail?id=2510889645","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510889645?lang=zh_tw&edition=fundamental","pubTime":"2025-02-10 14:58","pubTimestamp":1739170729,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示，MSCI中国医疗指数2025年初至今累计上涨5.3%，跑赢MSCI中国指数0.9%。医疗设备招标加速复苏，将推动国产医疗设备企业盈利复苏。该行认为，中国将成为海外药企寻找创新药管线的必选之地，中国创新药将在国际舞台扮演愈加重要的角色。丙类医保目录计划年内落地，商业医疗保险助力打开创新药支付天花板。该行认为，医保预付金和即时结算制度将有效缓解产业链的资金压力，利好商业流通、医疗机构等。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1952816","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995583.HKD","LU1046422090.SGD","01801","600056","02367","BK0028","BK0082","BK0250","LU1969619763.USD","BK0188","LU0052750758.USD","LU0196878994.USD","BK1141","LU0320764599.SGD","BK0185","BK1161","BK0175","BK0010","06990","BK1589","BK1576","LU2328871848.SGD","LU2488822045.USD","LU2045819591.USD","LU2125910500.SGD","02359","BK1207","01530","LU2242644610.SGD","BK1593","BK1583"],"gpt_icon":0},{"id":"2510207759","title":"招銀國際：看好中國醫藥行業估值修復 推薦“買入”藥明康德(02359)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2510207759","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510207759?lang=zh_tw&edition=fundamental","pubTime":"2025-02-10 09:46","pubTimestamp":1739151985,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研究报告称，看好中国医药行业估值修复。招银国际主要观点如下：MSCI中国医疗指数2025年初至今累计上涨5.3%，跑赢MSCI中国指数0.9%。该行认为，中国将成为海外药企寻找创新药管线的必选之地，中国创新药将在国际舞台扮演愈加重要的角色。国家医保局将采取多种激励措施，积极引导支持商业健康保险将丙类目录药品纳入保障范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1247554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2125910500.SGD","LU1997245094.SGD","LU1046422090.SGD","BK0082","LU2242644610.SGD","LU0320764599.SGD","02359","01530","BK1593","LU0456842615.SGD","LU1969619763.USD","06990","LU0196878994.USD","LU1997245177.USD","BK1589","BK0175","BK1207","02367","BK1141","BK0010","BK1161","LU2045819591.USD","LU2328871848.SGD","BK1583","BK0250","LU2488822045.USD","LU0052750758.USD","LU0708995583.HKD","BK0188","BK0028","603259","BK0185","BK0216","01801","600056","BK1576"],"gpt_icon":0},{"id":"2509707334","title":"科倫博泰生物與控股股東科倫藥業續簽物業及設備租賃協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2509707334","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509707334?lang=zh_tw&edition=fundamental","pubTime":"2025-02-08 09:58","pubTimestamp":1738979880,"startTime":"0","endTime":"0","summary":"财中社2月8日电科伦博泰生物-B 发布公告，董事会已于2025年1月28日决定续订与控股股东科伦药业的2025年物业租赁协议及2025年设备租赁协议，租期自2025年1月1日起至2027年12月31日止。2025年物业租赁协议的年租金为896万元，使用权资产的价值约为2260万元；而2025年设备租赁协议的年租金为3955万元，使用权资产的价值约为9580万元。董事会认为，此次交易的条款公平合理，符合公司及股东的整体利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208100238961bb062&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208100238961bb062&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1542","BK1258","BK1161","03913","BK1229","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2509179285","title":"科倫博泰生物-B(06990)：西妥昔單抗N01注射液獲國家藥品監督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2509179285","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509179285?lang=zh_tw&edition=fundamental","pubTime":"2025-02-07 17:04","pubTimestamp":1738919058,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，公司自主研发的重组表皮生长因子受体人鼠嵌合单克隆抗体(单抗)西妥昔单抗N01注射液(达泰莱)已获中国国家药品监督管理局批准于中国上市，适应症为与FOLFOX或FOLFIRI方案联合用于一线治疗RAS基因野生型的转移性结直肠癌，500mg/m2每两周一次，或者起始剂量400mg/m2、维持剂量250mg/m2每周一次。西妥昔单抗N01注射液的获批，将为晚期结直肠癌的临床治疗带来更多可及药物选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1247123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物-B(06990)：西妥昔单抗N01注射液获国家药品监督管理局批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2509792316","title":"科倫博泰生物－Ｂ(06990.HK)治療直腸癌注射液獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2509792316","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509792316?lang=zh_tw&edition=fundamental","pubTime":"2025-02-07 17:01","pubTimestamp":1738918860,"startTime":"0","endTime":"0","summary":"科伦博泰生物－Ｂ(06990.HK) 公布，公司自主研发的重组表皮生长因子受体(EGFR)人鼠嵌合单克隆抗体西妥昔单抗N01注射液已获国家药监局批准于中国上市，适应症为与FOLFOX或FOLFIRI方案联合用于一线治疗RAS基因野生型的转移性结直肠癌，500 mg/m2每两周一次，或者起始剂量400 mg/m2、维持剂量250 mg/m2每周一次。(ha/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-07 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230904161536655_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230904161536655_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1415684/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2509292821","title":"科倫博泰生物-B現漲近6% 和鉑醫藥宣佈HBM9378/SKB378獲批臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2509292821","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509292821?lang=zh_tw&edition=fundamental","pubTime":"2025-02-06 11:55","pubTimestamp":1738814100,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　科伦博泰生物-B（06990）早盘上涨5.73%，现报171.50港元，成交额1263.42万港元。\n　　和铂医药宣布，集团针对胸腺基质淋巴细胞生成素的全人源单克隆抗体HBM9378/SKB378已获得国家药监局药品审评中心的新药研究申请批件，以开展治疗慢性阻塞性肺病的临床试验。据悉，HBM9378/SKB378为公司与科伦博泰开展的共同开发项目，二者共同享有大中华地区及多个东南亚及西亚国家的权利。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-06/doc-ineiphxi4394833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","LU0196878994.USD","BK1161","BK1141","02142","BK1583","03347","BK1576","06990"],"gpt_icon":0},{"id":"2509949322","title":"科倫博泰生物-B(06990)上漲5.12%，報170.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2509949322","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509949322?lang=zh_tw&edition=fundamental","pubTime":"2025-02-06 11:38","pubTimestamp":1738813119,"startTime":"0","endTime":"0","summary":"2月6日，科伦博泰生物-B(06990)盘中上涨5.12%，截至11:38，报170.5元/股，成交1159.29万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司，主要以抗体药物偶联物（ADC）的技术平台为基础，致力于解决全球普遍或难以治疗的癌症以及众多患人医疗需求未满足的其他疾病。公司拥有完善的一体化药物开发机制，已建立包含研发、生产、质量控制及商业化等全面功能的一体化能力，并有30多款差异化且具有临床价值的资产管线，其中10余款处于临床阶段。截至2024年中报，科伦博泰生物-B营业总收入13.83亿元、净利润3.1亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/06113847980245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2509294335","title":"科倫博泰生物-B盤中異動 臨近午盤股價大漲5.12%報170.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509294335","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509294335?lang=zh_tw&edition=fundamental","pubTime":"2025-02-06 11:38","pubTimestamp":1738813113,"startTime":"0","endTime":"0","summary":"2025年02月06日临近午盘11时38分，科伦博泰生物-B股票出现波动，股价快速拉升5.12%。截至发稿，该股报170.500港元/股，成交量6.97万股，换手率0.05%，振幅7.21%。资金方面，该股资金流入549.859万港元，流出484.681万港元。科伦博泰生物-B股票所在的生物技术行业中，整体涨幅为1.84%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206113833abc42bea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206113833abc42bea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2509291645","title":"港股異動 | 科倫博泰生物-B(06990)再漲近5% 和鉑醫藥宣佈HBM9378/SKB378獲批臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2509291645","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509291645?lang=zh_tw&edition=fundamental","pubTime":"2025-02-06 11:26","pubTimestamp":1738812419,"startTime":"0","endTime":"0","summary":"消息面上，和铂医药宣布，集团针对胸腺基质淋巴细胞生成素的全人源单克隆抗体HBM9378/SKB378已获得国家药监局药品审评中心的新药研究申请批件，以开展治疗慢性阻塞性肺病的临床试验。据悉，HBM9378/SKB378为公司与科伦博泰开展的共同开发项目，二者共同享有大中华地区及多个东南亚及西亚国家的权利。此前，NMPA已批准塔戈利单抗单药用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者于中国上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1246432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1576","BK1583","BK1161","LU0196878994.USD","02142","03347","BK1574","BK1141"],"gpt_icon":0},{"id":"2508345150","title":"科倫博泰生物-B擬實施H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2508345150","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508345150?lang=zh_tw&edition=fundamental","pubTime":"2025-02-03 08:47","pubTimestamp":1738543620,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　科伦博泰生物-B（06990）发布公告，公司董事会已审议及批准公司若干股东所持不超过约2542.12万股公司内资股拟实施全流通（“H股全流通”）。同日，公司已向中国证监会提交关于H股全流通的备案申请。\n　　于本公告日期，H股全流通尚须取得所有相关批准（包括中国证监会的备案通知），以及将该等股份转换为本公司H股及香港联合交易所有限公司上市委员会批准H股于联交所主板上市及买卖（“转换并上市”）。H股全流通最终实施数量将取决于该等相关批准情况。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-02-03/doc-ineiefen5349729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2506159060","title":"【科倫博泰生物-B(06990.HK)擬實施H股全流通】科倫博泰生物-B(06990.HK)發佈公告，公司董事會已審議及批准公司若干股東所持不超過約2542.12萬股公司內資股擬實施全流通(“H股全流通”)。同日，公司已向中國證監會提交關於H股全流通的備案申請。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506159060","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506159060?lang=zh_tw&edition=fundamental","pubTime":"2025-01-28 20:20","pubTimestamp":1738066850,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B(06990.HK)发布公告，公司董事会已审议及批准公司若干股东所持不超过约2542.12万股公司内资股拟实施全流通(“H股全流通”)。同日，公司已向中国证监会提交关于H股全流通的备案申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/28202047881455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2506262597","title":"科倫博泰生物-B(06990)擬實施H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2506262597","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506262597?lang=zh_tw&edition=fundamental","pubTime":"2025-01-28 20:07","pubTimestamp":1738066023,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，公司董事会已审议及批准公司若干股东所持不超过约2542.12万股公司内资股拟实施全流通(“H股全流通”)。同日，公司已向中国证监会提交关于H股全流通的备案申请。于本公告日期，H股全流通尚须取得所有相关批准(包括中国证监会的备案通知)，以及将该等股份转换为本公司H股及香港联合交易所有限公司上市委员会批准H股于联交所主板上市及买卖(“转换并上市”)。H股全流通最终实施数量将取决于该等相关批准情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1244984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2506345703","title":"科倫博泰生物-B盤中異動 股價大跌5.04%報160.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506345703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506345703?lang=zh_tw&edition=fundamental","pubTime":"2025-01-27 13:40","pubTimestamp":1737956433,"startTime":"0","endTime":"0","summary":"2025年01月27日下午盘13时40分，科伦博泰生物-B股票出现波动，股价大幅下挫5.04%。截至发稿，该股报160.200港元/股，成交量5.77万股，换手率0.04%，振幅5.75%。资金方面，该股资金流入300.043万港元，流出449.605万港元。科伦博泰生物-B股票所在的生物技术行业中，整体涨幅为0.39%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012713403398743e0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012713403398743e0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2506345161","title":"科倫博泰生物－Ｂ(06990)股價下跌5.039%，現價港幣$160.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2506345161","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506345161?lang=zh_tw&edition=fundamental","pubTime":"2025-01-27 13:40","pubTimestamp":1737956400,"startTime":"0","endTime":"0","summary":"[下跌股]科伦博泰生物－Ｂ(06990) 股价在下午01:40比前收市价下跌5.039%，现股价为港币$160.2。至目前为止，今日最高价为$169.9，而最低价为$160.2。总成交量为5.77万股，总成交金额为港币$944.697万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2501271795/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2506335863","title":"格隆匯個股放量排行榜 | 1月26日","url":"https://stock-news.laohu8.com/highlight/detail?id=2506335863","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506335863?lang=zh_tw&edition=fundamental","pubTime":"2025-01-26 17:30","pubTimestamp":1737883803,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日EDA集团控股(02505)、粤海置地(00124)、赛伯乐国际控股(01020)、出门问问(02438)、商汤-WR(80020)、畅捷通(01588)、京东方精电(00710)、地平线机器人-W(09660)、第四范式(06682)、连连数字(02598)、中国智能科技(00464)、满贯集团(03390)、美团-WR(83690)、FIT HON TENG(0","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/26173047831469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01302","00659","01728","02460","00815","00464","06682","09995","00204","01815","06601","02236","01880","00565","02155","01020","02038","06616","01997","01186","02799","00124","06060","06055","00631","00412","00697","00241","00264","01252","00370","06990","01357","06626","06996","03339","00308","02196","02359","00288","02309","00511","03709","02505","03931","01088"],"gpt_icon":1},{"id":"2505008651","title":"科倫博泰生物-B盤中異動 早盤股價大漲5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505008651","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505008651?lang=zh_tw&edition=fundamental","pubTime":"2025-01-24 10:32","pubTimestamp":1737685947,"startTime":"0","endTime":"0","summary":"2025年01月24日早盘10时32分，科伦博泰生物-B股票出现异动，股价快速拉升5.09%。截至发稿，该股报171.300港元/股，成交量4.25万股，换手率0.03%，振幅5.09%。科伦博泰生物-B股票所在的生物技术行业中，整体涨幅为0.66%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124103227abb690ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124103227abb690ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盤後","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盤後","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2941,"buy":0.7059,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7059,"analysts":17,"updateTime":1744646400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-04-17","current":-228.611836,"percent":0.03653,"low":-257.850518,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"high":-21.029201,"avg":-97.473315,"sd":62.021902,"marketCap":64862287200},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200}],"updateTime":1745156687961}}}